6h
Hosted on MSNLeerink Partners Downgrades 10x Genomics (TXG)Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...
Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.29. Operator: Thank you for standing by. My name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results